- AU$217.65m
- AU$200.61m
- NZ$103.85m
Australia's Aroa Biosurgery falls to record low as Bell Potter cuts TP
Brief: Aroa Biosurgery Says Guidance Reduced For FY24
Brief: Aroa Biosurgery Says HY Loss After Tax Attributable NZ$6.3 Million
ASX-listed Aroa Biosurgery gains on positive outlook
Brief: Aroa Biosurgery Says FY24 Product Revenue Guidance Maintained At NZ$72-75 Mln
Brief: Aroa Biosurgery Says FY24 Product Revenue Guidance Maintained At NZ$72-75 Million
ASX-listed Aroa Biosurgery falls on posting second consecutive annual loss
ASX-listed Aroa Biosurgery falls on second consecutive annual loss
Brief: Aroa Biosurgery Says Preliminary Unaudited FY23 Normalised EBITDA Positive
Tela Bio slides on pricing $45 mln equity offering
Aroa Biosurgery remains among top picks in medtech post Enivo clearance - Canaccord
Brief: Aroa Biosurgery Receives U.S. FDA 510K Clearance For Its Enivo Pump And Catheter
Brief: Aroa Biosurgery Says Aroa Awarded Reg Skin Grafting Products Deal
Brief: Aroa Biosurgery Sees FY23 Total Revenue Guidance Maintained At NZ$62-64 Mln
Australia's Aroa Biosurgery hits over 2-month high on bullish results
Brief: Aroa Biosurgery Says Total Revenue Guidance For FY23 Of NZ$62-64 Million
Brief: Aroa Biosurgery Says FY23 Product Revenue Guidance Maintained At NZ$51-55 Mln
ASX-listed Aroa Biosurgery hits over 2-week high on FY23 outlook
ASX-Listed Aroa Biosurgery climbs on higher annual revenue